These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 36229514)
1. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models. Kahsay A; Rodriguez-Marquez E; López-Pérez A; Hörnblad A; von Hofsten J Sci Rep; 2022 Oct; 12(1):17149. PubMed ID: 36229514 [TBL] [Abstract][Full Text] [Related]
2. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors. de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386 [TBL] [Abstract][Full Text] [Related]
3. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
4. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Calhabeu F; Hayashi S; Morgan JE; Relaix F; Zammit PS Oncogene; 2013 Jan; 32(5):651-62. PubMed ID: 22710712 [TBL] [Abstract][Full Text] [Related]
6. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643 [TBL] [Abstract][Full Text] [Related]
7. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488 [TBL] [Abstract][Full Text] [Related]
8. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma]. Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543 [TBL] [Abstract][Full Text] [Related]
10. Genetic compensation between Pax3 and Pax7 in zebrafish appendicular muscle formation. Nord H; Kahsay A; Dennhag N; Pedrosa Domellöf F; von Hofsten J Dev Dyn; 2022 Sep; 251(9):1423-1438. PubMed ID: 34435397 [TBL] [Abstract][Full Text] [Related]
11. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427 [TBL] [Abstract][Full Text] [Related]
12. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931 [TBL] [Abstract][Full Text] [Related]
13. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Tiffin N; Williams RD; Shipley J; Pritchard-Jones K Br J Cancer; 2003 Jul; 89(2):327-32. PubMed ID: 12865925 [TBL] [Abstract][Full Text] [Related]
14. Classification of rhabdomyosarcoma and its molecular basis. Parham DM; Barr FG Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309 [TBL] [Abstract][Full Text] [Related]
15. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]